Department of Medical, Surgical and Health Sciences, Section of Otolaryngology, University of Trieste, Trieste, Italy.
Department of Medical, Surgical and Health Sciences, Section of Otolaryngology, University of Trieste, Trieste, Italy.
Am J Otolaryngol. 2023 Sep-Oct;44(5):103944. doi: 10.1016/j.amjoto.2023.103944. Epub 2023 Jun 8.
Despite alterations in the sense of smell and taste have dominated the symptoms of SARS-CoV-2 infection, the prevalence and the severity of self-reporting COVID-19 associated olfactory and gustatory dysfunction has dropped significantly with the advent of the Omicron BA.1 subvariant. However, data on the evolution of Omicron-related chemosensory impairment are still lacking.
The aim of the present study was to estimate the prevalence and the recovery rate of self-reported chemosensory dysfunction 6-month after SARS-CoV-2 infection acquired during the predominance of the Omicron BA.1 subvariant in Italy.
Prospective observational study based on the sino-nasal outcome tool 22 (SNOT-22), item "sense of smell or taste" and additional outcomes conducted in University hospitals and tertiary referral centers in Italy.
Of 338 patients with mild-to-moderate COVID-19 completing the baseline survey, 294 (87.0 %) responded to the 6-month follow-up interview. Among them, 101 (34.4 %) and 4 (1.4 %) reported an altered sense of smell or taste at baseline and at 6 months, respectively. Among the 101 patients with COVID-19-associated smell or taste dysfunction during the acute phase of the disease, 97 (96.0 %) reported complete resolution at 6 months. The duration of smell or taste impairment was significantly shorter in vaccinated patients (p = 0.007).
Compared with that observed in subjects infected during the first wave of the pandemic, the recovery rate from chemosensory dysfunctions reported in the present series of patients infected during the predominance of the Omicron BA.1 subvariant was more favorable with a shorter duration being positively influenced by vaccination.
尽管嗅觉和味觉改变在 SARS-CoV-2 感染的症状中占主导地位,但随着 Omicron BA.1 亚变体的出现,自我报告的 COVID-19 相关嗅觉和味觉功能障碍的患病率和严重程度已显著下降。然而,关于 Omicron 相关化学感觉障碍演变的数据仍然缺乏。
本研究旨在评估意大利 Omicron BA.1 亚变体流行期间感染 SARS-CoV-2 后 6 个月自我报告化学感觉障碍的患病率和恢复率。
前瞻性观察研究,基于鼻-鼻窦结局工具 22(SNOT-22)、“嗅觉或味觉”项目和其他结局,在意大利的大学医院和三级转诊中心进行。
在完成基线调查的 338 例轻度至中度 COVID-19 患者中,有 294 例(87.0%)对 6 个月随访进行了应答。其中,101 例(34.4%)和 4 例(1.4%)分别在基线和 6 个月时报告嗅觉或味觉改变。在疾病急性阶段有 COVID-19 相关嗅觉或味觉功能障碍的 101 例患者中,97 例(96.0%)在 6 个月时报告完全缓解。疫苗接种患者的嗅觉或味觉障碍持续时间明显更短(p=0.007)。
与在大流行第一波感染的患者中观察到的相比,本系列在 Omicron BA.1 亚变体流行期间感染的患者中报告的化学感觉功能障碍的恢复率更有利,持续时间更短,且疫苗接种具有积极影响。